|
1) Huggins C, Hodges CV. Studies on prostatic cancer: effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293-7
|
|
|
|
|
2) Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513-20
|
|
|
|
|
3) Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-12
|
|
|
|
|
|
4) Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996; 14: 1756-64
|
|
|
|
|
|
5) Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999; 17: 2506-13
|
|
|
|
|
|
6) Berry W, Dakhil S, Modiano M, et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 2002; 168: 2439-43
|
|
|
|
|
|
7) Reed DJ Double identity for proteins of the Bcl-2 family. Nature. 1997; 387: 773-6
|
|
|
|
|
|
8) Jurgensmeier JM, Xie Z, Deveraux Q, et al. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A. 1998; 95: 4997-5002
|
|
|
|
|
|
9) Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol. 1993; 143: 390-400
|
|
|
|
|
|
10) McDonnell TJ, Navone NM, Troncoso P, et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol. 1997; 157: 569-74
|
|
|
|
|
|
11) McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992; 52: 6940-4
|
|
|
|
|
|
12) Raffo AJ, Perlman H, Chen MW, et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 1995; 55: 4438-45
|
|
|
|
|
|
13) Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 1996; 56(6): 1253-5
|
|
|
|
|
|
14) Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008; 26: 242-5
|
|
|
|
|
|
15) Calabro F, Sternberg CN. Current indications for chemotherapy in prostate cancer patients. Eur Urol. 2007; 51: 17-26
|
|
|
|
|
|
16) Choy H, Park C, Yao M. Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res. 2008; 14: 1633-8
|
|
|
|
|
|
17) Sternberg CN, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology. 2005; 68: 2-9
|
|
|
|
|
|
18) Petrylak D, Sartor O, Witjes F, et al. A phase III, randomized, double-blind trial of satraplatin and prednisone vs. placebo and prednisone for patients with hormone-refractory prostate cancer (HRPC). Prostate Cancer Symposium. 2007; Abstract 145
|
|
|
|
|
|
19) Sternberg CN, Petrylak D, Witjes F, et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial. Proc Am Soc Clin Oncol. 2007; 25: abstract 5019
|
|
|
|
|
|
20) Hussain M, Tangen CM, Lara PN Jr, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol. 2005; 23: 8724-9
|
|
|
|
|
|
21) Rosenberg JE, Galsky MD, Rohs NC, et al. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer. 2006; 106: 58-62
|
|
|
|
|
|
22) Rosenberg JE, Galsky MD, Rohs NC, et al. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol. 2008; [Epub ahead of print]
|
|
|
|
|
|
23) Inoue T, Kobayashi T, Terada N, et al. Roles of androgen-dependent and -independent activation of signal transduction pathways for cell proliferation of prostate cancer cells. Expert Review of Endocrinology & Metabolism. 2007; 5: 689-704
|
|
|
|
|